John Pears

1.2k total citations
22 papers, 976 citations indexed

About

John Pears is a scholar working on Surgery, Economics and Econometrics and Molecular Biology. According to data from OpenAlex, John Pears has authored 22 papers receiving a total of 976 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Surgery, 7 papers in Economics and Econometrics and 5 papers in Molecular Biology. Recurrent topics in John Pears's work include Lipoproteins and Cardiovascular Health (9 papers), Cancer, Lipids, and Metabolism (5 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). John Pears is often cited by papers focused on Lipoproteins and Cardiovascular Health (9 papers), Cancer, Lipids, and Metabolism (5 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). John Pears collaborates with scholars based in United Kingdom, United States and Sweden. John Pears's co-authors include Anders Olsson, Susan S. Harris, Howard G. Hutchinson, John McKellar, Ali Raza, Donald G. Vidt, Michael D. Cressman, John Senior, Paul J. Seligman and Daniel J. Rader and has published in prestigious journals such as Hepatology, The American Journal of Cardiology and Biochemical Pharmacology.

In The Last Decade

John Pears

21 papers receiving 933 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Pears United Kingdom 12 645 309 273 193 96 22 976
Rebecca Bakker‐Arkema United States 12 654 1.0× 201 0.7× 308 1.1× 163 0.8× 48 0.5× 25 882
D B Hunninghake United States 14 669 1.0× 174 0.6× 375 1.4× 113 0.6× 62 0.6× 30 1.1k
Aditi Sapre United States 13 882 1.4× 191 0.6× 420 1.5× 274 1.4× 36 0.4× 23 1.2k
Peter H. Jones United States 9 780 1.2× 220 0.7× 349 1.3× 174 0.9× 42 0.4× 13 1.1k
Phillip D. Toth United States 11 1.3k 1.9× 382 1.2× 586 2.1× 254 1.3× 33 0.3× 25 1.8k
Reagan H. Bradford United States 21 992 1.5× 265 0.9× 457 1.7× 208 1.1× 96 1.0× 43 1.7k
Christine McCrary Sisk United States 21 897 1.4× 181 0.6× 588 2.2× 205 1.1× 32 0.3× 54 1.4k
David Neff United States 17 938 1.5× 299 1.0× 394 1.4× 233 1.2× 21 0.2× 39 1.4k
Mohamed A. Omar Canada 13 464 0.7× 135 0.4× 113 0.4× 69 0.4× 57 0.6× 31 968
Elinor Miller United States 11 1.4k 2.2× 599 1.9× 567 2.1× 352 1.8× 40 0.4× 19 1.7k

Countries citing papers authored by John Pears

Since Specialization
Citations

This map shows the geographic impact of John Pears's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Pears with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Pears more than expected).

Fields of papers citing papers by John Pears

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Pears. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Pears. The network helps show where John Pears may publish in the future.

Co-authorship network of co-authors of John Pears

This figure shows the co-authorship network connecting the top 25 collaborators of John Pears. A scholar is included among the top collaborators of John Pears based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Pears. John Pears is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nixon, Richard M., Shahrul Mt‐Isa, Thaison Tong, et al.. (2015). A case study using the PrOACT‐URL and BRAT frameworks for structured benefit risk assessment. Biometrical Journal. 58(1). 8–27. 27 indexed citations
2.
Ozer, Josef, Anne Lanevschi, Ina Schuppe‐Koistinen, et al.. (2010). A Systematic Approach to Preclinical and Clinical Safety Biomarker Qualification Incorporating Bradford Hill's Principles of Causality Association. Clinical Pharmacology & Therapeutics. 88(2). 260–262. 7 indexed citations
3.
Watkins, Paul B., Paul J. Seligman, John Pears, Mark Avigan, & John Senior. (2008). Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology. 48(5). 1680–1689. 84 indexed citations
4.
Storlien, L. H., Xu‐Feng Huang, Linda C Tapsell, et al.. (2005). Lifestyle-Gene-Drug Interactions in Relation to the Metabolic Syndrome. World review of nutrition and dietetics. 94. 84–95. 2 indexed citations
5.
Shepherd, James, Donald B. Hunninghake, Evan A. Stein, et al.. (2004). Safety of rosuvastatin. The American Journal of Cardiology. 94(7). 882–888. 115 indexed citations
6.
Vidt, Donald G., Michael D. Cressman, Susan S. Harris, John Pears, & Howard G. Hutchinson. (2004). Rosuvastatin-Induced Arrest in Progression of Renal Disease. Cardiology. 102(1). 52–60. 122 indexed citations
7.
Rader, Daniel J., Michael H. Davidson, Richard Caplan, & John Pears. (2003). Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. The American Journal of Cardiology. 91(5). 20–23. 69 indexed citations
8.
Caslake, Muriel, Grace Stewart, Stephen Day, et al.. (2003). Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Atherosclerosis. 171(2). 245–253. 82 indexed citations
9.
Hamilton‐Craig, Ian, Ernst J. Schaefer, Michel Farnier, et al.. (2003). Rosuvastatin produces significantly greater reductions in low-density lipoprotein cholesterol and more patients achieve treatment goals compared with simvastatin. Heart Lung and Circulation. 12(2). A41–A42. 3 indexed citations
10.
Shepherd, Jonathan, et al.. (2003). 2P-0613 Safety profile of rosuvastatin 10–40 mg in an intergnational phase II/III clinical trial program. Atherosclerosis Supplements. 4(2). 174–175.
11.
Olsson, Anders, Helge Istad, O Luurila, et al.. (2002). Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. American Heart Journal. 144(6). 1044–1051. 154 indexed citations
12.
Olsson, Anders, et al.. (2001). Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. The American Journal of Cardiology. 88(5). 504–508. 175 indexed citations
13.
14.
Olsson, A G, et al.. (2000). Pharmacodynamics of new HMG-CoA reductase inhibitor ZD4522 in patients with primary hypercholesterolaemia. Atherosclerosis. 151(1). 39–39. 14 indexed citations
15.
Pears, John, et al.. (1992). A case of skin hyperpigmentation due to α-MSH hypersecretion. British Journal of Dermatology. 126(3). 286–289. 24 indexed citations
16.
Pears, John, Roland Jung, Janusz Jankowski, Ian D. Waddell, & Ann N. Burchell. (1992). Glucose-6-phosphatase in normal adult human intestinal mucosa. Clinical Science. 83(6). 683–687. 9 indexed citations
17.
Pears, John, R. T. Jung, M C Browning, Roy Taylor, & Ann N. Burchell. (1991). Reactive Hypoglycaemia in Association with Disordered Islet Function and Abnormal Hepatic Glucose‐6‐Phosphatase Activity: Response to Diazoxide. Diabetic Medicine. 8(3). 268–271. 7 indexed citations
18.
Pears, John & Peter Sandercock. (1990). Benign Intracranial Hypertension Associated with Danazol. Scottish Medical Journal. 35(2). 49–49. 6 indexed citations
19.
Coughtrie, Michael W.H., John Pears, Alwen L. Jones, & Ann N. Burchell. (1990). Cytosolic phenol and steroid sulphotransferase activities are decreased in a sex-dependent manner in streptozotocin-induced diabetic rats. Biochemical Pharmacology. 40(9). 2180–2183. 8 indexed citations
20.
Pears, John, Roland Jung, & Ann N. Burchell. (1989). Amiloride activation of hepatic microsomal glucose-6-phosphatase; activation of T1?. Biochimica et Biophysica Acta (BBA) - General Subjects. 993(2-3). 224–227. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rebecca Bakker‐Arkema Breakdown of academic impact, for papers by D B Hunninghake Breakdown of academic impact, for papers by Aditi Sapre Breakdown of academic impact, for papers by Peter H. Jones Breakdown of academic impact, for papers by Phillip D. Toth Breakdown of academic impact, for papers by Reagan H. Bradford Breakdown of academic impact, for papers by Christine McCrary Sisk Breakdown of academic impact, for papers by David Neff Breakdown of academic impact, for papers by Mohamed A. Omar Breakdown of academic impact, for papers by Elinor Miller
Rankless by CCL
2026